Advanced Science,
Journal Year:
2024,
Volume and Issue:
unknown
Published: July 26, 2024
Engineered
bacteria-mediated
antitumor
approaches
have
been
proposed
as
promising
immunotherapies
for
cancer.
However,
the
off-target
bacterial
toxicity
narrows
therapeutic
window.
Living
microbes
will
benefit
from
their
controllable
immunogenicity
within
tumors
safer
applications.
In
this
study,
a
genetically
encoded
microbial
activation
strategy
is
reported
that
uses
tunable
and
dynamic
expression
of
surface
extracellular
polysaccharides
to
improve
biocompatibility
while
retaining
efficacy.
Based
on
screening
genes
associated
with
Salmonella
survival
in
macrophages,
novel
attenuated
chassis
strain
AIS
(htrA
gene-deficient)
highly
enriched
after
administration
rapidly
cleared
normal
organs
are
reported.
Subsequently,
an
engineered
strain,
AISI-H,
constructed
based
optimized
quorum-sensing
regulatory
system.
The
AISI-H
can
achieve
recovery
tumor-specific
virulence
through
HTRA-RCSA
axis-based
synthetic
gene
circuit-mediated
increase
polysaccharide
content.
These
strains
act
"off"
avoid
unwanted
immune
"on"
precise
tumor
suppression
mice.
shows
significant
inhibition
potent
anticancer
immunity
melanoma
mouse
model.
exhibits
excellent
biocompatibility.
This
regulation
expands
applications
microbe-based
therapeutics.
Science,
Journal Year:
2023,
Volume and Issue:
382(6667), P. 211 - 218
Published: Oct. 12, 2023
A
major
challenge
facing
tumor-antigen
targeting
therapies
such
as
chimeric
antigen
receptor
(CAR)-T
cells
is
the
identification
of
suitable
targets
that
are
specifically
and
uniformly
expressed
on
heterogeneous
solid
tumors.
By
contrast,
certain
species
bacteria
selectively
colonize
immune-privileged
tumor
cores
can
be
engineered
antigen-independent
platforms
for
therapeutic
delivery.
To
bridge
these
approaches,
we
developed
a
platform
probiotic-guided
CAR-T
(ProCARs),
in
which
tumor-colonizing
probiotics
release
synthetic
label
tissue
CAR-mediated
lysis
situ.
This
system
demonstrated
cell
activation
antigen-agnostic
was
safe
effective
multiple
xenograft
syngeneic
models
human
mouse
cancers.
We
further
multifunctional
co-release
chemokines
to
enhance
recruitment
response.
Signal Transduction and Targeted Therapy,
Journal Year:
2024,
Volume and Issue:
9(1)
Published: July 22, 2024
Abstract
Cytokines
are
critical
in
regulating
immune
responses
and
cellular
behavior,
playing
dual
roles
both
normal
physiology
the
pathology
of
diseases
such
as
cancer.
These
molecules,
including
interleukins,
interferons,
tumor
necrosis
factors,
chemokines,
growth
factors
like
TGF-β,
VEGF,
EGF,
can
promote
or
inhibit
growth,
influence
microenvironment,
impact
efficacy
cancer
treatments.
Recent
advances
targeting
these
pathways
have
shown
promising
therapeutic
potential,
offering
new
strategies
to
modulate
system,
progression,
overcome
resistance
conventional
therapies.
In
this
review,
we
summarized
current
understanding
implications
cytokine
chemokine
signaling
By
exploring
molecules
biology
response,
highlighted
development
novel
agents
aimed
at
modulating
combat
The
review
elaborated
on
nature
cytokines
promoters
suppressors
tumorigenesis,
depending
context,
discussed
challenges
opportunities
presents
for
intervention.
We
also
examined
latest
advancements
targeted
therapies,
monoclonal
antibodies,
bispecific
receptor
inhibitors,
fusion
proteins,
engineered
variants,
their
metastasis,
microenvironment.
Additionally,
evaluated
potential
combining
therapies
with
other
treatment
modalities
improve
patient
outcomes.
Besides,
focused
ongoing
research
clinical
trials
that
pivotal
advancing
our
application
cytokine-
chemokine-targeted
patients.
Nature Communications,
Journal Year:
2023,
Volume and Issue:
14(1)
Published: June 15, 2023
Here,
we
provide
a
brief
overview
of
the
approaches
and
strategies
underlying
bacteria-based
cancer
immunotherapy
(BCiT).
We
also
describe
summarize
research
in
field
synthetic
biology,
which
aims
to
regulate
bacterial
growth
gene
expression
for
immunotherapeutic
use.
Finally,
discuss
current
clinical
status
limitations
BCiT.
Advanced Materials,
Journal Year:
2023,
Volume and Issue:
unknown
Published: July 12, 2023
Abstract
Natural
living
materials
serving
as
biotherapeutics
exhibit
great
potential
for
treating
various
diseases
owing
to
their
immunoactivity,
tissue
targeting,
and
other
biological
activities.
In
this
review,
the
recent
developments
in
engineered
materials,
including
mammalian
cells,
bacteria,
viruses,
fungi,
microalgae,
plants,
active
derivatives
that
are
used
summarized.
Further,
future
perspectives
challenges
of
such
material‐based
discussed
provide
considerations
advances
biomedical
applications.
Advanced Materials,
Journal Year:
2023,
Volume and Issue:
36(8)
Published: Nov. 7, 2023
Bacterial-based
delivery
strategies
have
recently
emerged
as
a
unique
research
direction
in
the
field
of
drug
delivery.
However,
bacterial
vectors
are
quickly
phagocytosed
by
immune
cells
after
entering
bloodstream.
Taking
advantage
this
phenomenon,
herein,
work
seeks
to
harness
potential
micron-sized
vectors,
and
find
that
inactivated
can
accumulate
at
tumor-site
intravenous
injection
through
CD11b
Current Opinion in Biotechnology,
Journal Year:
2024,
Volume and Issue:
85, P. 103061 - 103061
Published: Jan. 13, 2024
Bacterial
therapeutics
have
emerged
as
promising
delivery
systems
to
target
tumors.
These
engineered
live
can
be
harnessed
modulate
the
tumor
microenvironment
or
deliver
and
selectively
release
therapeutic
payloads
A
major
challenge
is
bacteria
systemically
without
causing
widespread
inflammation,
which
critical
for
many
tumors
that
are
not
accessible
direct
intratumoral
injection.
We
describe
potential
strategies
address
this
challenge,
along
with
approaches
specific
payload
biocontainment
ensure
safety.
will
pave
way
development
of
cost-effective,
widely
applicable
next-generation
cancer
therapeutics.
Cell Reports,
Journal Year:
2024,
Volume and Issue:
43(4), P. 114086 - 114086
Published: April 1, 2024
Immune
checkpoint
blockade
(ICB)
has
revolutionized
cancer
therapy
but
only
works
in
a
subset
of
patients
due
to
the
insufficient
infiltration,
persistent
exhaustion,
and
inactivation
T
cells
within
tumor.
Herein,
we
develop
an
engineered
probiotic
(interleukin
[IL]-12
nanoparticle
Escherichia
coli
Nissle
1917
[INP-EcN])
acting
as
living
drug
factory
biosynthesize
anti-PD-1
release
IL-12
for
initiating
systemic
antitumor
immunity
through
cell
cascade
regulation.
Mechanistically,
INP-EcN
not
continuously
biosynthesizes
relieving
immunosuppression
also
effectively
promote
activation,
proliferation,
infiltration
via
responsive
IL-12,
thus
reaching
sufficient
activation
threshold
ICB.
Tumor
targeting
colonization
INP-EcNs
dramatically
increase
local
accumulations,
significantly
inhibiting
tumor
growth
metastasis
compared
commercial
inhibitors.
Furthermore,
immune
profiling
reveals
that
anti-PD-1/IL-12
efficiently
effects
CD8
BMEMat,
Journal Year:
2024,
Volume and Issue:
unknown
Published: July 17, 2024
Abstract
Immunotherapy
has
recently
emerged
as
a
promising
therapeutic
modality
for
the
treatment
of
various
diseases
such
cancer,
inflammation,
autoimmune
diseases,
and
infectious
diseases.
Despite
its
potential,
immunotherapy
faces
challenges
related
to
delivery
efficiency
off‐target
toxicity
immunotherapeutic
drugs.
Nano
drug
systems
offer
improvements
in
biodistribution
release
kinetics
but
still
suffer
from
shortcomings
high
immunogenicity,
poor
penetration
across
biological
barriers,
insufficient
tissue
permeability.
Targeted
drugs
using
living
cells
become
an
emerging
strategy
that
can
take
advantage
inherent
characteristics
deal
with
defects
nano
systems.
Furthermore,
themselves
be
genetically
engineered
into
cellular
enhanced
immunotherapy.
This
review
provides
in‐depth
exploration
cell‐derived
carriers,
detailing
their
properties,
functions,
commonly
used
loading
strategies.
In
addition,
role
modified
synergistic
effects
are
also
introduced.
By
summarizing
main
advancements
limitations
field,
this
offers
insights
potential
cell‐based
address
existing
The
introduction
recent
developments
evaluation
ongoing
research
will
pave
way
optimization
widespread
adoption
nano/genetically
